Last reviewed · How we verify

TAU

Montefiore Medical Center · FDA-approved active Small molecule

Tau protein aggregation inhibitor.

Tau protein aggregation inhibitor. Used for Alzheimer's disease.

At a glance

Generic nameTAU
Also known asTreatment as Usual, Usual care, Treatment As Usual
SponsorMontefiore Medical Center
Drug classTau protein aggregation inhibitor
TargetTau protein
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Tau protein aggregation is a hallmark of neurodegenerative diseases such as Alzheimer's disease. TAU inhibits this aggregation, potentially slowing disease progression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: